Therapeutics: MAP kinase 7 (MAPK7; BMK1; ERK-5); mitogen-activated protein kinase kinase kinase 2 (MAP3K2); WNK lysine deficient protein kinase 1 (WNK1; PPP1R16

Cancer

INDICATION: Prostate cancer

Patient sample, mouse and cell culture studies suggest inhibiting MAPK7 or the MAPK7 pathway components MAP3K2 and

Read the full 193 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE